Salivary and serum levels of soluble E-cadherin in patients with gastrointestinal cancers: A comparative study.
Journal
Journal of cancer research and therapeutics
ISSN: 1998-4138
Titre abrégé: J Cancer Res Ther
Pays: India
ID NLM: 101249598
Informations de publication
Date de publication:
01 Oct 2023
01 Oct 2023
Historique:
received:
30
03
2022
accepted:
20
05
2022
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
20
2
2024
Statut:
ppublish
Résumé
According to the literature, high levels of salivary soluble E-cadherin may be lined to advanced stage and poor prognosis in cancers. This research aimed at comparing salivary and serum levels of soluble E-cadherin in cases with esophageal, gastric, and colorectal cancers. This case-control research was performed on 68 patients with gastrointestinal cancers and 57 healthy volunteers as a control group to measure salivary and serum levels of soluble E-cadherin using ELISA kits. The results showed a statistically significant difference between salivary and serum levels of soluble E-cadherin in the case group, as opposed to the control group (P = 0.031). The salivary level of soluble E-cadherin in the control group was 2.138 ng/mL on average lower than that that in the case group. The median salivary level of soluble E-cadherin among cases with lymph node involvement was significantly higher compared with its median level in the control group (P = 0.049). Soluble E-cadherin salivary level and other variables, such as metastasis and cancer stage, were directly correlated, but it was not statistically significant. According to the findings, the salivary level of soluble E-cadherin among cases with gastric cancer could be considered as a prognostic marker, but the diagnostic value of saliva could not be judged in esophageal and colorectal cancers because of small sample size, and more investigations are required for a definite conclusion.
Identifiants
pubmed: 38376307
doi: 10.4103/jcrt.jcrt_702_22
pii: 01363817-202319070-00041
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1982-1987Informations de copyright
Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016;66:7–30
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018:GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53
Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001;48:808–11
Okugawa Y, Toiyama Y, Inoue Y, Iwata T, Fujikawa H, Saigusa S, et al. Clinical significance of serum soluble E-cadherin in colorectal carcinoma. J Surg Res 2012;175:67–73
Repetto O, De Paoli P, De Re V, Canzonieri V, Cannizzaro R. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. Biomed Res Int 2014;2014:408047
Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, et al. Tissue invasion and metastasis:Molecular, biological and clinical perspectives. Semin Cancer Bio 2015;35:S244–75
Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC. Beyond a tumor suppressor:Soluble E-cadherin promotes the progression of cancer. Int J Cancer 2016;138:2804–12
Daulagala AC, Bridges MC, Kourtidis A. E-cadherin beyond structure:A signaling hub in colon homeostasis and disease. Int J Mol Sci 2019;20:2756
Wilmanns C, Grossmann J, Steinhauer S, Manthey G, Weinhold B, Schmitt-Gräff A, et al. Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients. Clin Exp Metastasis 2004;21:75–8
Grabowska MM, Day ML. Soluble E-cadherin:More than a symptom of disease. Front Bio sci (Landmark Ed) 2012;17:1948–64
Chan AO, Chu KM, Lam SK, Wong BC, Kwok KF, Law S, et al. Soluble E-cadherin is an independent pretherapeutic factor for long-term survival in gastric cancer. J Clin Oncol 2003;21:2288–93
Christou N, Perraud A, Blondy S, Jauberteau MO, Battu S, Mathonnet M. E-cadherin:A potential biomarker of colorectal cancer prognosis. Oncol lett 2017;13:4571–6
Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 2010;11:3106–21
Zimmermann BG, Park NJ, Wong DT. Genomic targets in saliva. Ann N Y Acad Sci 2007;1098:184–91
Tsaur I, Thurn K, Juengel E, Gust KM, Borgmann H, Mager R, et al. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. J Exp Clin Cancer Res 2015;34:43
López-Verdín S, Soto-Avila JJ, Zamora-Perez AL, Lazalde-Ramos BP, Martínez-Fierro ML, González-González R, et al. Patients with advanced oral squamous cell carcinoma have high levels of soluble E-cadherin in the saliva. Med Oral Patol Oral Cir Bucal 2017;22:694–701
Rawla P, Barsouk A. Epidemiology of gastric cancer:Global trends, risk factors and prevention. Prz Gastroenterol 2019;14:26–38
Weiss JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W, et al. Soluble E-cadherin as a serum biomarker candidate:Elevated levels in patients with late-stage colorectal carcinoma and FAP. Int J Cancer 2011;128:1384–92
Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I, et al. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994;69:580–5
Velikova G, Banks R, Gearing A, Hemingway I, Forbes MA, Preston SR, et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 1998;77:1857–63
Tsalikidis C, Papachristou F, Pitiakoudis M, Asimakopoulos B, Trypsianis G, Bolanaki E, et al. Soluble E-cadherin as a diagnostic and prognostic marker in gastric carcinoma. Folia Med (Plovdiv) 2013;55:26–32
Jiang L, Hochwald S, Deng S, Zhu Y, Chunyan Y, Tan C, et al. Evaluation of EGF, EGFR, and E-cadherin as potential biomarkers for gastrointestinal cancers. Front Lab Med 2017;1:135–40
Velikova G, Banks R, Gearing A, Hemingway I, Forbes MA, Preston SR, et al. Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. Br J Cancer 1997;76:1398–404
Juhasz M, Ebert MP, Schulz HU, Röcken C, Molnar B, Tulassay Z, et al. Dual role of serum soluble E-cadherin as a biological marker of metastatic development in gastric cancer. Scand J Gastroenterol 2003;38:850–5
De Wever O, Derycke L, Hendrix A, Meerleer GD, Godeau F, Depypere H, et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 2007;24:685–97
Parrish AR, Catania JM, Orozco J, Gandolfi AJ. Chemically induced oxidative stress disrupts the E-cadherin/catenin cell adhesion complex. Toxicol Sci 1999;50:80–6